Association between the NIH composite 0-3 score (clinician measure) or Lee Symptom Scale (patient measure) and OS and NRM
| . | OS . | NRM . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| NIH composite 0-3 skin score | ||||
| Score at enrollment | ||||
| 3 vs 0 | 2.9 (1.5 ∼ 5.7) | .001 | 4.5 (2.2 ∼ 9.4) | < .001 |
| Change at 6 mo | ||||
| Improve | 1.2 (0.3 ∼ 4.3) | .81 | 1.0 (0.2 ∼ 3.8) | .94 |
| Worsen | 4.7 (0.9 ∼ 25.1) | .07 | 7.2 (1.2 ∼ 43.9) | .03 |
| Change at 12 mo | ||||
| Improve | 1.6 (0.3 ∼ 9.6) | .58 | 0.9 (0.1 ∼ 6.6) | .91 |
| Worsen | 1.7 (0.2 ∼ 16.4) | .65 | 3.1 (0.3 ∼ 34.9) | .37 |
| Skin subscale, Lee Symptom Scale | ||||
| Score at enrollment | ||||
| > 15 points | 2.3 (1.3 ∼ 3.8) | .002 | 2.9 (1.6 ∼ 5.4) | .001 |
| Change at 6 mo | ||||
| Improve | 0.07 (0.008 ∼ 0.6) | .01 | 0.09 (0.01 ∼ 0.8) | .03 |
| Worsen | 1.6 (0.4 ∼ 6.0) | .46 | 2.1 (0.5 ∼ 8.3) | .29 |
| Change at 12 mo | ||||
| Improve | 0.4 (0.03 ∼ 5.7) | .50 | 0.3 (0.02 ∼ 4.0) | .35 |
| Worsen | 3.4 (0.5 ∼ 21.1) | .19 | 4.0 (0.6 ∼ 28.1) | .17 |
| . | OS . | NRM . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| NIH composite 0-3 skin score | ||||
| Score at enrollment | ||||
| 3 vs 0 | 2.9 (1.5 ∼ 5.7) | .001 | 4.5 (2.2 ∼ 9.4) | < .001 |
| Change at 6 mo | ||||
| Improve | 1.2 (0.3 ∼ 4.3) | .81 | 1.0 (0.2 ∼ 3.8) | .94 |
| Worsen | 4.7 (0.9 ∼ 25.1) | .07 | 7.2 (1.2 ∼ 43.9) | .03 |
| Change at 12 mo | ||||
| Improve | 1.6 (0.3 ∼ 9.6) | .58 | 0.9 (0.1 ∼ 6.6) | .91 |
| Worsen | 1.7 (0.2 ∼ 16.4) | .65 | 3.1 (0.3 ∼ 34.9) | .37 |
| Skin subscale, Lee Symptom Scale | ||||
| Score at enrollment | ||||
| > 15 points | 2.3 (1.3 ∼ 3.8) | .002 | 2.9 (1.6 ∼ 5.4) | .001 |
| Change at 6 mo | ||||
| Improve | 0.07 (0.008 ∼ 0.6) | .01 | 0.09 (0.01 ∼ 0.8) | .03 |
| Worsen | 1.6 (0.4 ∼ 6.0) | .46 | 2.1 (0.5 ∼ 8.3) | .29 |
| Change at 12 mo | ||||
| Improve | 0.4 (0.03 ∼ 5.7) | .50 | 0.3 (0.02 ∼ 4.0) | .35 |
| Worsen | 3.4 (0.5 ∼ 21.1) | .19 | 4.0 (0.6 ∼ 28.1) | .17 |
Each model includes either the NIH composite skin score or the Lee Symptom Scale as the covariate of interest, and controls for study site and for factors associated with chronic GVHD health outcomes (months from HCT to cohort enrollment, case type, platelet count at chronic GVHD onset, Karnofsky performance status at chronic GVHD onset, patient age at transplantation, donor type, donor-patient gender combination, and prior history of acute GVHD).
NIH indicates National Institutes of Health; OS, overall survival; NRM, nonrelapse mortality; HCT, hematopoietic cell transplantation; HR, hazard ratio; and CI, confidence interval.
Bold values represent HRs with P ≤ .01.